The effects of statin monotherapy and low-dose statin/ezetimibe on lipoprotein-associated phospholipase A2

Sang Hak Lee, Seok Min Kang, Sungha Park, Yangsoo Jang, Namsik Chung, Donghoon Choi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background Many of the pleiotropic effects of statins remain to be elucidated. Hypothesis Different statin regimens with similar lipid-lowering efficacy may have different effects on biomarkers of atherothrombosis including lipoprotein-associated phospholipase A2 (Lp-PLA2). Methods After a 4-week dietary lead-in, 82 hypercholesterolemic patients were randomized to 1 of 2 treatment groups: atorvastatin 20 mg or atorvastatin/ezetimibe 5 mg/5 mg. After 8 weeks of drug treatment, the groups were compared for percent change in lipid parameters, Lp-PLA2, interleukin-6 (IL-6), monocyte chemoattractant protein-1, and fibrinogen. Results Low-density lipoprotein cholesterol (LDL-C) lowering was comparable between the 2 groups (-47% ± 11% and -49% ± 7% in the atorvastatin and combination groups, respectively). Although Lp-PLA2 was reduced in both groups, the reduction was greater in the atorvastatin group (-42% and -9% [median], respectively, P = 0.03). Although IL-6 was decreased only in the atorvastatin group, IL-6 changes were not significantly different between the 2 groups. The changes in monocyte chemoattractant protein-1 and fibrinogen were similar in each group. Conclusions Atorvastatin monotherapy was stronger at reducing plasma Lp-PLA2 than the low-dose atorvastatin/ezetimibe combination after equivalent LDL-C lowering. This result may provide evidence of potential statin effects beyond the lowering of LDL-C.

Original languageEnglish
Pages (from-to)108-112
Number of pages5
JournalClinical Cardiology
Volume34
Issue number2
DOIs
Publication statusPublished - 2011 Feb 1

Fingerprint

1-Alkyl-2-acetylglycerophosphocholine Esterase
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Interleukin-6
Chemokine CCL2
LDL Cholesterol
Fibrinogen
Lipids
Atorvastatin Calcium
Ezetimibe
Biomarkers

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

@article{4f328afc53494f0b9bcbe18451303a07,
title = "The effects of statin monotherapy and low-dose statin/ezetimibe on lipoprotein-associated phospholipase A2",
abstract = "Background Many of the pleiotropic effects of statins remain to be elucidated. Hypothesis Different statin regimens with similar lipid-lowering efficacy may have different effects on biomarkers of atherothrombosis including lipoprotein-associated phospholipase A2 (Lp-PLA2). Methods After a 4-week dietary lead-in, 82 hypercholesterolemic patients were randomized to 1 of 2 treatment groups: atorvastatin 20 mg or atorvastatin/ezetimibe 5 mg/5 mg. After 8 weeks of drug treatment, the groups were compared for percent change in lipid parameters, Lp-PLA2, interleukin-6 (IL-6), monocyte chemoattractant protein-1, and fibrinogen. Results Low-density lipoprotein cholesterol (LDL-C) lowering was comparable between the 2 groups (-47{\%} ± 11{\%} and -49{\%} ± 7{\%} in the atorvastatin and combination groups, respectively). Although Lp-PLA2 was reduced in both groups, the reduction was greater in the atorvastatin group (-42{\%} and -9{\%} [median], respectively, P = 0.03). Although IL-6 was decreased only in the atorvastatin group, IL-6 changes were not significantly different between the 2 groups. The changes in monocyte chemoattractant protein-1 and fibrinogen were similar in each group. Conclusions Atorvastatin monotherapy was stronger at reducing plasma Lp-PLA2 than the low-dose atorvastatin/ezetimibe combination after equivalent LDL-C lowering. This result may provide evidence of potential statin effects beyond the lowering of LDL-C.",
author = "Lee, {Sang Hak} and Kang, {Seok Min} and Sungha Park and Yangsoo Jang and Namsik Chung and Donghoon Choi",
year = "2011",
month = "2",
day = "1",
doi = "10.1002/clc.20853",
language = "English",
volume = "34",
pages = "108--112",
journal = "Clinical Cardiology",
issn = "0160-9289",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

The effects of statin monotherapy and low-dose statin/ezetimibe on lipoprotein-associated phospholipase A2. / Lee, Sang Hak; Kang, Seok Min; Park, Sungha; Jang, Yangsoo; Chung, Namsik; Choi, Donghoon.

In: Clinical Cardiology, Vol. 34, No. 2, 01.02.2011, p. 108-112.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effects of statin monotherapy and low-dose statin/ezetimibe on lipoprotein-associated phospholipase A2

AU - Lee, Sang Hak

AU - Kang, Seok Min

AU - Park, Sungha

AU - Jang, Yangsoo

AU - Chung, Namsik

AU - Choi, Donghoon

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Background Many of the pleiotropic effects of statins remain to be elucidated. Hypothesis Different statin regimens with similar lipid-lowering efficacy may have different effects on biomarkers of atherothrombosis including lipoprotein-associated phospholipase A2 (Lp-PLA2). Methods After a 4-week dietary lead-in, 82 hypercholesterolemic patients were randomized to 1 of 2 treatment groups: atorvastatin 20 mg or atorvastatin/ezetimibe 5 mg/5 mg. After 8 weeks of drug treatment, the groups were compared for percent change in lipid parameters, Lp-PLA2, interleukin-6 (IL-6), monocyte chemoattractant protein-1, and fibrinogen. Results Low-density lipoprotein cholesterol (LDL-C) lowering was comparable between the 2 groups (-47% ± 11% and -49% ± 7% in the atorvastatin and combination groups, respectively). Although Lp-PLA2 was reduced in both groups, the reduction was greater in the atorvastatin group (-42% and -9% [median], respectively, P = 0.03). Although IL-6 was decreased only in the atorvastatin group, IL-6 changes were not significantly different between the 2 groups. The changes in monocyte chemoattractant protein-1 and fibrinogen were similar in each group. Conclusions Atorvastatin monotherapy was stronger at reducing plasma Lp-PLA2 than the low-dose atorvastatin/ezetimibe combination after equivalent LDL-C lowering. This result may provide evidence of potential statin effects beyond the lowering of LDL-C.

AB - Background Many of the pleiotropic effects of statins remain to be elucidated. Hypothesis Different statin regimens with similar lipid-lowering efficacy may have different effects on biomarkers of atherothrombosis including lipoprotein-associated phospholipase A2 (Lp-PLA2). Methods After a 4-week dietary lead-in, 82 hypercholesterolemic patients were randomized to 1 of 2 treatment groups: atorvastatin 20 mg or atorvastatin/ezetimibe 5 mg/5 mg. After 8 weeks of drug treatment, the groups were compared for percent change in lipid parameters, Lp-PLA2, interleukin-6 (IL-6), monocyte chemoattractant protein-1, and fibrinogen. Results Low-density lipoprotein cholesterol (LDL-C) lowering was comparable between the 2 groups (-47% ± 11% and -49% ± 7% in the atorvastatin and combination groups, respectively). Although Lp-PLA2 was reduced in both groups, the reduction was greater in the atorvastatin group (-42% and -9% [median], respectively, P = 0.03). Although IL-6 was decreased only in the atorvastatin group, IL-6 changes were not significantly different between the 2 groups. The changes in monocyte chemoattractant protein-1 and fibrinogen were similar in each group. Conclusions Atorvastatin monotherapy was stronger at reducing plasma Lp-PLA2 than the low-dose atorvastatin/ezetimibe combination after equivalent LDL-C lowering. This result may provide evidence of potential statin effects beyond the lowering of LDL-C.

UR - http://www.scopus.com/inward/record.url?scp=79751486106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79751486106&partnerID=8YFLogxK

U2 - 10.1002/clc.20853

DO - 10.1002/clc.20853

M3 - Article

C2 - 21298654

AN - SCOPUS:79751486106

VL - 34

SP - 108

EP - 112

JO - Clinical Cardiology

JF - Clinical Cardiology

SN - 0160-9289

IS - 2

ER -